Live Breaking News & Updates on Jeeadv

Stay updated with breaking news from Jeeadv. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Gil Yosipovitch, MD: Overview of Current Research on Prurigo Nodularis

During this interview segment, Dr. Yosipovitch discussed his overview of current PN research and a specific study he had presented at EADV.
....

Gil Yosipovitch , Miller School Of Medicine , University Of Miami , European Academy Of Dermatology , Miller School , Prurigo Nodularis ,

Gil Yosipovitch, MD: New Analysis of Data on Patient Satisfaction with Dupilumab for Prurigo Nodularis

This discussion with Dr. Yosipovitch covered findings presented at EADV 2023 on dupilumab and prurigo nodularis patients’ satisfaction.
....

Gil Yosipovitch , European Academy Of Dermatology , University Of Miami , Miller School Of Medicine , Miller School , Nature Medicine , Prurigo Nodularis ,

New Phase 3 Data Suggest Long-Term Efficacy of Upadacitinib in Atopic Dermatitis

The data presents compelling evidence for the sustained efficacy and safety of the oral JAK1 inhibitor in the treatment of moderate to severe atopic dermatitis over an extended 140-week period. ....

European Association Of Dermatology , Dermatology Times , European Association , Eczema Area , Severity Index , Observed Cases , Worst Pruritus Numeric Rating Scale , Atopic Dermatitis ,

Latest Phase 3 Trial Data Announced for Upadacitinib Treatment of Atopic Dermatitis

This new data was presented at EADV in Berlin, with the findings of 3 studies expanding the range of effectiveness of this treatment to 140-weeks for patients with eczema.
....

Jonathan Silverberg , George Washington University School Of Medicine , Health Sciences , European Academy Of Dermatology , European Academy , George Washington University School , Eczema Area , Severity Index , Global Assessment , Atopic Dermatitis , Vie Presents Long Term Data Further Supporting , Safety Profile , Severe Atopic ,

New 3-Year Extension Study Results Observed for Deucravacitinib Treatment of Plaque Psoriasis

The new data on this drug’s effects on maintenance of clinical response indicates the strength of the treatment for individuals with the immune-mediated skin disease.
....

April Armstrong , Aprilw Armstrong , Kunzmannk Lauren Miller , European Academy Of Dermatology , Bristol Myers Squibb , Drug Administration , European Academy , Psoriasis Area , Severity Index , Global Assessment , Long Term Data Demonstrate Durable Efficacy , Consistent Safety , Three Years , Moderate To Severe Plaque , Bristol Myers , Merging Care , Plaque Psoriasis ,